BioSpace News Archive

Wovenware, a nearshore provider of Artificial Intelligence (AI) and digital transformation solutions, announced today that it has been chosen as the software and AI development partner of choice for CDI Labs, a Puerto Rico-based global biotechnology firm.

RedHill Biopharma Ltd. today announced that members of its board of directors and senior management, including the Company’s Chairman & CEO, Mr. Dror Ben-Asher, collectively purchased approximately an additional 66,000 American Depositary Shares (ADSs) of RedHill since mid-October, 2021, in open-market transactions.

FibroBiologics, a clinical-stage company developing fibroblast cell-based therapeutics for chronic diseases, today introduced its scientific advisory board (SAB).

Y-mAbs Therapeutics, Inc. today announced that clinical experience for naxitamab and data from the Company’s SADA technology programs will be presented at the Company’s R&D event, which will take place virtually today at 12 p.m. Eastern Time.

GenXys Healthcare Systems Inc. (GenXys) is adding a new value dimension to Precision Genetics and the personalized health marketplace.

BioIQ, Inc., (“BioIQ”) and DermTech, Inc. (NASDAQ: DMTK) (“DermTech”), a leader in precision dermatology enabled by a non-invasive skin genomics platform, today announced an agreement to bring increased patient access to precision genomics.

Formedix, a leading provider of clinical trial software solutions, announces the launch of the Formedix ryze Community, to provide their customers with a location to collaborate, expand their knowledge and share information.

Lyell Immunopharma, Inc. (Lyell), (Nasdaq: LYEL), announced today that its LyFE Manufacturing Center in Bothell, Washington has been commissioned and qualified in compliance with the U.S. Food and Drug Administration’s (FDA’s) Current Good Manufacturing Practices (cGMP).

Enzo Biochem, Inc. (NYSE:ENZ), a leading biosciences and diagnostics company, today reported financial results for the first quarter ended October 31, 2021 and provided a business update on recent corporate and operational developments.

Verrica Pharmaceuticals Inc. (“Verrica”) (Nasdaq: VRCA), today announced that the U.S. Food and Drug Administration (FDA) acknowledged that Verrica’s resubmitted New Drug Application (NDA) for VP-102 for the treatment of molluscum contagiosum (molluscum) was complete and assigned a Prescription Drug User Fee Act (PDUFA) goal date of May 24, 2022.